Higher vitamin B6 status is associated with improved survival among patients with stage I–III colorectal cancer

Autor: Andreana N Holowatyj, Jennifer Ose, Biljana Gigic, Tengda Lin, Arve Ulvik, Anne JMR Geijsen, Stefanie Brezina, Rama Kiblawi, Eline H van Roekel, Andreas Baierl, Jürgen Böhm, Martijn JL Bours, Hermann Brenner, Stéphanie O Breukink, Jenny Chang-Claude, Johannes HW de Wilt, William M Grady, Thomas Grünberger, Tanja Gumpenberger, Esther Herpel, Michael Hoffmeister, Eric TP Keulen, Dieuwertje E Kok, Janna L Koole, Katharina Kosma, Ewout A Kouwenhoven, Gry Kvalheim, Christopher I Li, Peter Schirmacher, Petra Schrotz-King, Marie C Singer, Fränzel JB van Duijnhoven, Henk K van Halteren, Kathy Vickers, F Jeroen Vogelaar, Christy A Warby, Evertine Wesselink, Per M Ueland, Alexis B Ulrich, Martin Schneider, Nina Habermann, Ellen Kampman, Matty P Weijenberg, Andrea Gsur, Cornelia M Ulrich
Přispěvatelé: Epidemiologie, RS: GROW - R1 - Prevention, Surgery, MUMC+: MA Heelkunde (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: American Journal of Clinical Nutrition, 116(2), 303-313
Am J Clin Nutr
The American Journal of Clinical Nutrition, 116, 2, pp. 303-313
The American Journal of Clinical Nutrition, 116, 303-313
American Journal of Clinical Nutrition, 116(2), 303-313. Oxford University Press
American Journal of Clinical Nutrition 116 (2022) 2
ISSN: 0002-9165
Popis: Background: Folate-mediated 1-carbon metabolism requires several nutrients, including vitamin B6. Circulating biomarker concentrations indicating high vitamin B6 status are associated with a reduced risk of colorectal cancer (CRC). However, little is known about the effect of B6 status in relation to clinical outcomes in CRC patients. Objectives: We investigated survival outcomes in relation to vitamin B6 status in prospectively followed CRC patients. Methods: A total of 2031 patients with stage I–III CRC participated in 6 prospective patient cohorts in the international FOCUS (folate-dependent 1-carbon metabolism in colorectal cancer recurrence and survival) Consortium. Preoperative blood samples were used to measure vitamin B6 status by the direct marker pyridoxal 5'-phosphate (PLP), as well as the functional marker HK-ratio (HKr)[3'hydroxykynurenine: (kynurenic acid + xanthurenic acid + 3'-hydroxy anthranilic acid + anthranilic acid)]. Using Cox proportional hazards regression, we examined associations of vitamin B6 status with overall survival (OS), disease-free survival (DFS), and risk of recurrence, adjusted for patient age, sex, circulating creatinine concentrations, tumor site, stage, and cohort. Results: After a median follow-up of 3.2 y for OS, higher preoperative vitamin B6 status as assessed by PLP and the functional marker HKr was associated with 16–32% higher all-cause and disease-free survival, although there was no significant association with disease recurrence (doubling in PLP concentration: HROS, 0.68; 95% CI: 0.59, 0.79; HRDFS, 0.84; 95% CI: 0.75, 0.94; HRRecurrence, 0.96; 95% CI: 0.84, 1.09; HKr: HROS, 2.04; 95% CI: 1.67, 2.49; HRDFS, 1.56; 95% CI: 1.31, 1.85; HRRecurrence, 1.21; 95% CI: 0.96,1. 52). The association of PLP with improved OS was consistent across colorectal tumor site (right-sided colon: HROS, 0.75; 95% CI: 0.59, 0.96; left-sided colon: HROS, 0.71; 95% CI: 0.55, 0.92; rectosigmoid junction and rectum: HROS, 0.61; 95% CI: 0.47, 0.78). Conclusion: Higher preoperative vitamin B6 status is associated with improved OS among stage I–III CRC patients. Am J Clin Nutr 2022;116:303–313.
Databáze: OpenAIRE
Externí odkaz: